Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion

Sponsor
Ain Shams Maternity Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT02694198
Collaborator
(none)
135
1
6
22.6

Study Details

Study Description

Brief Summary

Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester abortion.

Condition or Disease Intervention/Treatment Phase
  • Other: fetal fibronectin measurement

Detailed Description

The population of the study will comprise 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol.

Before entering the study, the purpose of this work will be clearly explained and verbal consent will be obtained from all patients enrolled in the study along with routine written informed consent as governed by the hospital rules.

All participants will be subjected to:
  1. History taking:

  2. Personal history: age and special habits

  3. Obstetric history (parity, history of abortions, previous cerculage and preterm labor). Gestational Age will be assigned by means of a combination of menstrual dating and ultrasonographic evaluation.

  4. Past medical history (hypersensitivity to misoprostol, chronic adrenal insufficiency and inherited porphyrias).

  5. Past history of previous cesarean section or other operations as hysterotomy and myomectomy.

  6. Examination:

  7. General examination: blood pressure, pulse, temperature, body weight.

  8. Abdominal examination: fundal level, presence of scar of previous operations, uterine contractions.

  9. Investigations:

  10. Laboratory: complete blood count, c-reactive protein titre, blood group.

  11. Pelvic ultrasound: to assess fetal viability, amount of liquor, gestational age, position of the placenta.

  12. Assessment of vaginal fetal fibronectin:

All Patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the fetal fibronectin kit will be used to collect a sample of secretions from the posterior fornix. The sample will be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2ml) is not found, vagina will be washed with 2ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.

According to Ain Shams University Maternity Hospital protocol, termination of pregnancy will be conducted as an inpatient procedure. Termination of pregnancy will be performed using misoprostol tablets (Misotac® Sigma 200 mcg per tablet). Misoprostol tablets will be introduced by vaginal routes initially (total 800 mcg). Following the initial dose, 2 misoprostol tablets (400 mcg) will be inserted into the vagina every 4 hours to a maximum of four doses. If the woman does not have adequate contractions, within 8 hours following the last dose, the same regimen will be repeated over the following 24 hours without the loading dose.

The induction to expulsion period will be defined as the time from commencement of misoprostol until fetal expulsion without exerting any fetal traction by caregiver. After expulsion of the fetus, the patients will receive 30 units of oxytocin on 500 cc Ringer solution slowly by intravenous infusion over 30 minutes for expulsion of the placenta. Surgical evacuation will be done when indicated.

The kits used to measure level of fetal fibronectin in vaginal sample (ZYMUTEST Fibronectin kits) were provided from Hyphen BioMed corporation , France. The ZYMUTEST Fibronectin kit is an one-step enzyme immuno-assay for measuring human Fibronectin in plasma, or in any fluid where fibronectin can be present.

Study Design

Study Type:
Observational
Actual Enrollment :
135 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion
Study Start Date :
Sep 1, 2015
Actual Primary Completion Date :
Mar 1, 2016
Actual Study Completion Date :
Mar 1, 2016

Outcome Measures

Primary Outcome Measures

  1. Cervicovaginal Fetal Fibronectin Level [72 hours]

    mean cervicovaginal fetal fibronectin level in women undergoing midtrimesteric induction of abortion

  2. Relation of Cervicovaginal Fetal Fibronectin Level to Duration of Induction of Abortion [72 hours]

    Difference between women who expulsed the fetus within 24 hours and women who expulsed the fetus in more than 24 hours as regarding cervicovaginal fetal fibronectin level (ng/ml)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Singleton pregnancy.

  • 14-24 weeks gestation..

  • Missed miscarriage

Exclusion Criteria:
  • History of pulmonary, hepatic, renal, or cardiovascular diseases.

  • History of previous cesarean section and other uterine surgeries as hysterotomy and myomectomy.

  • Inevitable abortion.

  • Placenta covering internal os.

  • History of any cervical surgery as cervical amputation, cauterization or dilatation.

  • Premature rupture of membranes.

  • Any vaginal bleeding.

  • Contraindications for misoprostol as hypersensitivity to misoprostol, chronic adrenal insufficiency and inherited porphyrias.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ain Shams maternity hospital Cairo Egypt

Sponsors and Collaborators

  • Ain Shams Maternity Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amr Ahmed Mahmoud Riad, Lecturer of obstetrics and gynecology, Ain Shams Maternity Hospital
ClinicalTrials.gov Identifier:
NCT02694198
Other Study ID Numbers:
  • fetal fibronectin
First Posted:
Feb 29, 2016
Last Update Posted:
May 16, 2016
Last Verified:
Apr 1, 2016
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided

Study Results

Participant Flow

Recruitment Details
Pre-assignment Detail
Arm/Group Title Mid-trimester Abortion
Arm/Group Description The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
Period Title: Overall Study
STARTED 135
COMPLETED 135
NOT COMPLETED 0

Baseline Characteristics

Arm/Group Title Mid-trimester Abortion
Arm/Group Description The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
Overall Participants 135
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]
28.4
(4.02)
Sex: Female, Male (Count of Participants)
Female
135
100%
Male
0
0%
Body mass index (kilograms per squared meter) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [kilograms per squared meter]
29.4
(2.31)
gestational age in weeks (weeks) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [weeks]
19.32
(1.91)
Outcome of induction of abortion (participants) [Number]
abortion in less than 24 hours
119
88.1%
abortion in more than 24 hours
13
9.6%
failed induction
3
2.2%

Outcome Measures

1. Primary Outcome
Title Cervicovaginal Fetal Fibronectin Level
Description mean cervicovaginal fetal fibronectin level in women undergoing midtrimesteric induction of abortion
Time Frame 72 hours

Outcome Measure Data

Analysis Population Description
Depending on Francesco et al., 2005 who found that Fetal fibronectin test positive in 19 among 270 (7.0%) women undergoing mid-trimester abortion. Assuming α=0.05 and confidence interval (CI)= 10.0% and by using PASS 11th release the minimal sample size is 120. With a possible 10% drop out of cases, the enrolled cases would be 135 cases.
Arm/Group Title Mid-trimester Abortion
Arm/Group Description The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
Measure Participants 135
Mean (Standard Deviation) [nanogram per milliliter]
39.4
(7.9)
2. Primary Outcome
Title Relation of Cervicovaginal Fetal Fibronectin Level to Duration of Induction of Abortion
Description Difference between women who expulsed the fetus within 24 hours and women who expulsed the fetus in more than 24 hours as regarding cervicovaginal fetal fibronectin level (ng/ml)
Time Frame 72 hours

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Mid-trimester Abortion
Arm/Group Description The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
Measure Participants 135
women aborted within 24 hours n=129
39.3
(7.71)
women aborted in more than 24 hours or failed n=6
40.4
(11.2)

Adverse Events

Time Frame All participants were closely monitored during the process of induction of abortion and over the following 24 hours following spontaneous expulsion or surgical removal of the placenta.
Adverse Event Reporting Description
Arm/Group Title Mid-trimester Abortion
Arm/Group Description The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
All Cause Mortality
Mid-trimester Abortion
Affected / at Risk (%) # Events
Total / (NaN)
Serious Adverse Events
Mid-trimester Abortion
Affected / at Risk (%) # Events
Total 0/135 (0%)
Other (Not Including Serious) Adverse Events
Mid-trimester Abortion
Affected / at Risk (%) # Events
Total 118/135 (87.4%)
Gastrointestinal disorders
Nausea 12/135 (8.9%) 12
Diarrhea 3/135 (2.2%) 3
Vomiting 5/135 (3.7%) 5
General disorders
Shivering 5/135 (3.7%) 5
Fever 6/135 (4.4%) 6
Surgical and medical procedures
Need for surgical removal of placenta 87/135 (64.4%) 87

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact

Name/Title amr ahmed mahmoud riad
Organization Ain Shams Maternity hospital
Phone 01005347179 ext +2
Email amr.riad@med.asu.edu.eg
Responsible Party:
Amr Ahmed Mahmoud Riad, Lecturer of obstetrics and gynecology, Ain Shams Maternity Hospital
ClinicalTrials.gov Identifier:
NCT02694198
Other Study ID Numbers:
  • fetal fibronectin
First Posted:
Feb 29, 2016
Last Update Posted:
May 16, 2016
Last Verified:
Apr 1, 2016